What is PT-141 (bremelanotide)?

PT-141, or bremelanotide, is a melanocortin-receptor agonist related to the pigmentation peptides. It acts centrally through the melanocortin system and is marketed as the prescription product Vyleesi in some jurisdictions.

What does research suggest about PT-141?

Clinical evidence supports its specific approved indication, and its central melanocortin-receptor agonism has been characterized in both human trials and animal studies. This gives it a stronger evidence base than most unapproved research peptides.

Yes, in some jurisdictions it is approved as a prescription medicine (Vyleesi) for a specific indication. It is prescription-only; material sold on the unregulated research market is not the approved product and lacks that oversight.

It is a prescription medicine that needs medical supervision because it can affect blood pressure. Safety depends on clinical oversight, and unverified research-market material carries additional unknown risks around purity and dosing.

What are the side effects of PT-141?

Commonly reported effects include nausea, flushing, and transient blood-pressure changes. Because it can raise blood pressure, it is used under medical supervision rather than as a general-purpose supplement.

What is the legal status of PT-141?

Bremelanotide is an approved prescription-only medicine in some jurisdictions, meaning it legally requires a prescription. Research-market sale and use outside of that framework is unregulated and not the same as the approved product.

How is PT-141 different from melanotan II, which it is related to?

They share a melanocortin-agonist lineage — PT-141 was studied as an analog and metabolite of melanotan II — but they are not interchangeable. Melanotan II is primarily discussed for pigmentation and was never approved as a medicine, while bremelanotide was developed specifically around the sexual-arousal effects of melanocortin signaling and reached regulatory approval for a narrow indication. Only the latter went through formal clinical evaluation for that use.

Why did the delivery route change from a nasal spray to an injection during development?

The earliest human formulation was intranasal, but that program encountered blood-pressure signals that stalled it. Developers reformulated the compound as an on-demand subcutaneous injection, which is the form that was ultimately approved. This is a useful reminder that a peptide's route of administration can materially change its safety and absorption profile — the molecule and its formulation are not the same thing.

Why does PT-141 come up in blood-pressure discussions specifically?

Melanocortin-receptor activation can influence cardiovascular parameters, and transient blood-pressure changes are among the documented effects tied to this compound's mechanism — which is one reason its approved use is prescription-only and supervised. This is educational context about why the melanocortin target draws cardiovascular scrutiny, not health guidance; questions about personal suitability belong with a licensed clinician.

Where can I buy PT-141 (Bremelanotide) and compare vendors?

Use the vendor comparison on this page. It shows only checked, product-specific links and identifies vendor claims, independent documentation and affiliate relationships separately. Availability and legal status can vary by country.

Sexual Health

Buy PT-141 (Bremelanotide) – Vendors, Prices, Testing and Evidence

Buy PT-141 (Bremelanotide)

Also known as: Bremelanotide · Vyleesi

Evidence grade B — Human, limitedRisk flag

Short answer

A melanocortin agonist approved as a prescription medicine. Research-market use is unregulated.

Where can you buy PT-141 (Bremelanotide)?

Crystal Peptides. The table lists only product-specific offers that were checked and for which a real destination exists. Missing prices, quantities, stock and laboratory details are not inferred.

What is known?

PT-141 is a melanocortin-receptor agonist related to the pigmentation peptides.

What is not established?

Clinical evidence supports its approved indication.

Safety

Can affect blood pressure and cause nausea; prescription medicine that needs supervision.

Regulatory status

Approved as a prescription medicine (Vyleesi) for a specific indication in some jurisdictions; prescription-only.

Not medical advice. This educational reference is not diagnosis, treatment, prescribing, dosing or emergency guidance. Consult a qualified professional before making health-related decisions.

Regulatory or safety concern: This substance may be unapproved for human use, affect the hormonal system, or be subject to regulator or anti-doping restrictions. Check the cited evidence and rules in your jurisdiction.

Vendor comparison

Buy PT-141 (Bremelanotide): compare vendors

The table lists only product-specific offers that were checked and for which a real destination exists. Missing prices, quantities, stock and laboratory details are not inferred.

Vendor	Product	Documentation	Shipping	Checked	Action
Crystal Peptides Code PEPTIDES10 −10% · discount code details Sponsored	PT-141 (Bremelanotide) research product	Vendor-supplied data COA stated as available Not independently documented	Europe See the localized country store	Jul 18, 2026	View at vendor

Crystal Peptides

PT-141 (Bremelanotide) research product

Code PEPTIDES10 −10% · discount code details

What is it?

PT-141 is a melanocortin-receptor agonist related to the pigmentation peptides.

Research and evidence

PT-141, known generically as bremelanotide and marketed as the prescription product Vyleesi, is a melanocortin-receptor agonist that sits in the sexual-health category of research peptides. It is structurally related to the melanocortin (pigmentation) peptide family and acts centrally rather than on the vascular system, distinguishing its proposed mechanism from that of conventional erectile-function drugs. Unlike most compounds circulating in the research-chemical market, bremelanotide has cleared formal clinical development for a specific indication and is an approved prescription medicine in some jurisdictions, which gives it a comparatively well-characterized profile.

The scientific interest in PT-141 centers on its central melanocortin-receptor agonism. By engaging melanocortin signaling in the nervous system rather than acting on blood flow directly, it has been studied as a mechanistically distinct approach within sexual-health pharmacology. Clinical evidence supports its approved indication, and the underlying melanocortin effects have been characterized in animal studies, giving the compound a stronger evidence base than the many peptides whose claims rest on preclinical or anecdotal data alone. It is important to separate this regulated, studied product from unregulated "research-market" material sold outside of a prescription context, where purity, dosing, and oversight are not guaranteed.

On the honest evidence and safety picture: bremelanotide is a prescription medicine that requires medical supervision because it can affect blood pressure and commonly causes nausea, flushing, and transient blood-pressure changes. It carries a risk flag and a restricted commercial status precisely because it is a regulated drug, not a general-use supplement. This page is an educational reference summarizing what published research and regulatory records indicate about PT-141; it does not provide dosing, protocols, sourcing, or medical advice, and any real-world use of an approved medicine should occur only under a qualified clinician's care.

Evidence grade: B

Clinical evidence supports its approved indication. Melanocortin effects characterised.

Human evidence

Clinical evidence supports its approved indication.

Animal and preclinical evidence

Melanocortin effects characterised.

Proposed mechanisms

Central melanocortin-receptor agonism

Safety concerns and known side effects

Can affect blood pressure and cause nausea; prescription medicine that needs supervision.

Nausea
Flushing
Transient blood-pressure changes

Regulatory status

Approved as a prescription medicine (Vyleesi) for a specific indication in some jurisdictions; prescription-only.

PT-141 (Bremelanotide) research timeline

1960s–1980s
The melanocortin peptide family and its receptors are characterized, establishing the biology later exploited by melanocortin-agonist drugs.
1990s
PT-141 (bremelanotide) is described as a metabolite and analog of the melanocortin peptide melanotan II, studied because early work suggested melanocortin agonism influenced sexual arousal in addition to pigmentation.
early-to-mid 2000s
A biopharmaceutical developer advances bremelanotide into human trials, initially testing an intranasal formulation for sexual dysfunction.
mid-to-late 2000s
Intranasal development is set back after trials raise blood-pressure concerns; the program is reworked toward an on-demand subcutaneous injection.
2010s
Subcutaneous bremelanotide is evaluated in controlled trials in premenopausal women, supporting the approved indication.
2019
The compound is approved as the prescription medicine Vyleesi for a specific indication (acquired hypoactive sexual desire disorder in certain premenopausal women), remaining prescription-only.

Frequently asked questions about PT-141 (Bremelanotide)

What is PT-141 (bremelanotide)?: PT-141, or bremelanotide, is a melanocortin-receptor agonist related to the pigmentation peptides. It acts centrally through the melanocortin system and is marketed as the prescription product Vyleesi in some jurisdictions.
What does research suggest about PT-141?: Clinical evidence supports its specific approved indication, and its central melanocortin-receptor agonism has been characterized in both human trials and animal studies. This gives it a stronger evidence base than most unapproved research peptides.
Is PT-141 approved?: Yes, in some jurisdictions it is approved as a prescription medicine (Vyleesi) for a specific indication. It is prescription-only; material sold on the unregulated research market is not the approved product and lacks that oversight.
Is PT-141 safe?: It is a prescription medicine that needs medical supervision because it can affect blood pressure. Safety depends on clinical oversight, and unverified research-market material carries additional unknown risks around purity and dosing.
What are the side effects of PT-141?: Commonly reported effects include nausea, flushing, and transient blood-pressure changes. Because it can raise blood pressure, it is used under medical supervision rather than as a general-purpose supplement.
What is the legal status of PT-141?: Bremelanotide is an approved prescription-only medicine in some jurisdictions, meaning it legally requires a prescription. Research-market sale and use outside of that framework is unregulated and not the same as the approved product.
How is PT-141 different from melanotan II, which it is related to?: They share a melanocortin-agonist lineage — PT-141 was studied as an analog and metabolite of melanotan II — but they are not interchangeable. Melanotan II is primarily discussed for pigmentation and was never approved as a medicine, while bremelanotide was developed specifically around the sexual-arousal effects of melanocortin signaling and reached regulatory approval for a narrow indication. Only the latter went through formal clinical evaluation for that use.
Why did the delivery route change from a nasal spray to an injection during development?: The earliest human formulation was intranasal, but that program encountered blood-pressure signals that stalled it. Developers reformulated the compound as an on-demand subcutaneous injection, which is the form that was ultimately approved. This is a useful reminder that a peptide's route of administration can materially change its safety and absorption profile — the molecule and its formulation are not the same thing.
Why does PT-141 come up in blood-pressure discussions specifically?: Melanocortin-receptor activation can influence cardiovascular parameters, and transient blood-pressure changes are among the documented effects tied to this compound's mechanism — which is one reason its approved use is prescription-only and supervised. This is educational context about why the melanocortin target draws cardiovascular scrutiny, not health guidance; questions about personal suitability belong with a licensed clinician.
Where can I buy PT-141 (Bremelanotide) and compare vendors?: Use the vendor comparison on this page. It shows only checked, product-specific links and identifies vendor claims, independent documentation and affiliate relationships separately. Availability and legal status can vary by country.

Common discussion areas

Approved useMelanocortin system

Sources

Editorial review and transparency

Written by: peptides.cx Editorial Team
Scientific reviewer: No named medical reviewer is currently assigned
Last editorial review: June 1, 2026
Last vendor check: July 18, 2026
Review method: Source review, claim verification, vendor-data separation and regulatory-context review.
Commercial disclosure and conflicts: Vendor relationships do not determine evidence or safety ratings. No named reviewer conflict is recorded because no named reviewer is assigned.

Editorial policy →Evidence grade →Vendor methodology →

Related on peptides.cx

Library →Vendor quality checklist →Safety →Affiliate code: PEPTIDES10